Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions.","authors":"Melissa C Leeolou, Justin L Jia, Jason Harris, Wilson Liao","doi":"10.1177/24755303251387126","DOIUrl":"10.1177/24755303251387126","url":null,"abstract":"<p><p>In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387126"},"PeriodicalIF":0.0,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12546093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding \"Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study\".","authors":"Joaquín Borras-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo-Uixeda","doi":"10.1177/24755303251387120","DOIUrl":"10.1177/24755303251387120","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387120"},"PeriodicalIF":0.0,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Trial of Coach-Supported, Smartphone-Delivered Cognitive Behavioral Therapy for Psoriasis With Comorbid Depression.","authors":"John S Barbieri, Megan H Noe, Nora Bensellam, Phoebe Holz, Bruna G O Wafae, Ellen Esther Anshelevich, Jasmine N Williams, Ivar Snorrason, Hilary Weingarden, Oliver Harrison, Sabine Wilhelm","doi":"10.1177/24755303251387099","DOIUrl":"10.1177/24755303251387099","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is associated with increased risk of depression. Although cognitive behavioral therapy (CBT) is an evidence-based treatment, access remains limited.</p><p><strong>Objectives: </strong>To evaluate the feasibility, acceptability, and preliminary efficacy of a smartphone-delivered, coach-led CBT program for depression among individuals with psoriasis.</p><p><strong>Methods: </strong>This single-arm, 8-week pilot study (Mindset trial, NCT06216691) enrolled adults with psoriasis and at least mild depressive symptoms (PHQ-9 ≥5). Participants engaged in a smartphone-based CBT program guided by bachelor's-level lay coaches. Primary outcomes were feasibility as evaluated by module completion and acceptability as evaluated by the Client Satisfaction Questionnaire-8 (CSQ-8]) and User Version of the Mobile Application Rating Scale (uMARS). Secondary outcomes included changes in the Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Appearance Anxiety Inventory, Skindex-16, and Psoriasis Symptom Inventory.</p><p><strong>Results: </strong>Of 30 participants, 63.3% completed ≥4/8 modules and 43.3% completed ≥6/8 modules. Mean CSQ-8 and uMARS scores were 27.2 (SD 4.5) and 4.0 (SD 0.7), respectively, supporting high satisfaction. Statistically and clinically significant improvements were observed in PHQ-9 (mean change -4.4; Cohen's d = 0.92), GAD-7 (-2.8; d = 0.63), and Skindex-16 symptoms (5.0; d = 0.78), emotions (10.0; d = 0.95), and functioning (6.4; Cohen's d = 0.71) subscales as well as the Psoriasis Symptom Inventory (3.1; d = 0.43).</p><p><strong>Conclusions: </strong>This study supports the feasibility, acceptability, and preliminary efficacy of smartphone-delivered CBT for individuals with psoriasis and depressive symptoms. Given the scalability of this model, future randomized trials are warranted to assess broader effectiveness in dermatology care settings.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387099"},"PeriodicalIF":0.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12507800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copay Accumulators: A Legislative Issue in Dermatology.","authors":"Melissa C Leeolou, Justin L Jia, Dayna L Pham, Jason Harris, Wilson Liao","doi":"10.1177/24755303251361815","DOIUrl":"10.1177/24755303251361815","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361815"},"PeriodicalIF":0.0,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Patient Priorities for Psoriatic Disease Research.","authors":"Georgia Marquez-Grap, Andrea Leung, Allison Kranyak, Krystal Adkins, Jessica Smith, Alicia O'Neal, Guy Eakin, Wilson Liao","doi":"10.1177/24755303251361816","DOIUrl":"10.1177/24755303251361816","url":null,"abstract":"<p><p><b>Background:</b> There have been significant advances in psoriatic disease research in recent years, leading to better understanding of genes involved and increased treatment options. <b>Purpose:</b> To guide current research priorities for psoriatic disease, we held an interactive session on this topic consisting of a presentation and small group discussion with National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. <b>Research design:</b> We presented a list of 10 psoriatic research topics and asked attendees to rate the priority of each topic on a 9-point scale. The session also included breakout groups where attendees discussed research areas most important to them. <b>Study Sample:</b> National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. <b>Data collection and/or Analysis:</b> Attendees completed an online REDCap survey which was then analyzed by the study team. <b>Results:</b> \"Improving treatment for psoriatic disease and achieving remission\" was the research topic that received the highest overall rating. We also learned of research topics of high patient interest not included on our original list of 10 topics, including research exploring the relationship between psoriatic disease and hormones, infertility, and menopause. Increased research on pediatric psoriatic disease and research initiatives focused on increased patient and provider education were topics of importance to attendees as well. <b>Conclusion:</b> Overall, these findings may help guide future patient-centered research agendas in psoriatic disease.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361816"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics.","authors":"Alexandra Lauren Rice, Sarah Gillespie, Nikhil Sai, Soumya M Reddy, Joseph F Merola, Rebecca H Haberman, Alexis Ogdie, Jose U Scher","doi":"10.1177/24755303251361800","DOIUrl":"10.1177/24755303251361800","url":null,"abstract":"<p><strong>Background: </strong>In order to apply current treatment recommendations for psoriatic arthritis (PsA), a complete assessment of psoriatic disease domains must be completed by the clinician. This includes a musculoskeletal examination (including tender and swollen joints, dactylitis, enthesitis, and axial disease) as well as skin and nail examination. Documentation in the clinician's note serves as a proxy for disease assessment.</p><p><strong>Objective: </strong>To explore differences in documentation of psoriatic domains between PsA specialist and general rheumatologists at 2 academic centers.</p><p><strong>Methods: </strong>We identified PsA patients seen by either general rheumatologists or by PsA combined clinic specialist providers at 2 established PPACMAN (Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network) sites. Records were assessed for the presence (and extent) of documentation for musculoskeletal and cutaneous PsA domains. We also examined accuracy of ICD coded diagnoses to understand the extent to which discrete data from the electronic medical record can be used to evaluate completeness of assessment.</p><p><strong>Results: </strong>PsA combined clinic specialist providers documented disease domains significantly more consistently compared to generalists, including tender and swollen joint counts (<i>P</i> < 0.001), assessment of spondyloarthritis (<i>P</i> = 0.017), and presence/extent of skin involvement (<i>P</i> < 0.001). Additionally, PsA specialists more consistently coded for both psoriasis (PsO) and PsA.</p><p><strong>Conclusions: </strong>In this multicenter, retrospective study, compared to generalists, PsA combined-clinic specialist providers more thoroughly documented both musculoskeletal and cutaneous psoriatic disease domains and ICD coding of PsO for patients, highlighting gaps in assessment and documentation. These findings underscore the need for improved training in psoriatic disease assessment and simplified modalities for documentation.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361800"},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey.","authors":"Omar Alani, Carrington Webb, Nashwah Memon, S Minhaj Rahman, Fahad Ahmed, Nicole Seminara, Adel Haque","doi":"10.1177/24755303251345804","DOIUrl":"10.1177/24755303251345804","url":null,"abstract":"<p><p>Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. This phone survey study evaluated 87 adults on RZB (n = 29), GUS (n = 35), or IXE (n = 23) from 2019 onward at two clinical sites. Patients were assessed for baseline PsO bothersome severity, current dosing frequency satisfaction, frequency of PsO flares, and preferred dosing frequency. Most patients were males (57.5%) with an average age of 54.1 years and an average treatment duration of 19.0 months. At baseline before treatment, 87% were 'very bothered' by their PsO. After treatment, 86% were either '3-somewhat' or '4-very satisfied' with their current dosing schedule, with no significant differences between each drug (<i>P</i> = 0.7). Across all biologics the majority of participants (62% with RZB, 57% with GUS, and 48% with IXE) preferred maintaining their current dosing frequency. No statistically significant differences were observed in dosing frequency preference between treatment groups, suggesting dosing schedule is not a primary concern for most patients. This aligns with previous research demonstrating effective disease control is the most important factor for patient satisfaction; however, tailoring dosing regimens to individual patient needs can also strengthen long-term adherence, as demonstrated in recent studies.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"131-133"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.","authors":"Alice B Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, Bhargav Lakshminarasimhan, Bruce Strober, Mark Lebwohl","doi":"10.1177/24755303251344155","DOIUrl":"10.1177/24755303251344155","url":null,"abstract":"<p><strong>Background: </strong>Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US.</p><p><strong>Objective: </strong>To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US.</p><p><strong>Methods: </strong>An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019. All-cause mortality was evaluated at 365 days post-index and at maximum follow-up in the following cohorts: <i>GPP-only</i>, <i>Plaque-PsO-only</i>, <i>GPP + PsO</i>, <i>All-GPP</i>, and <i>general population</i>. Propensity score matching was used to balance covariates between cohorts. The index date was the first medical claim for GPP (ICD-10 code L40.1) or PsO (L40.0), and a randomly selected date per year for individuals in the <i>general population</i> cohort.</p><p><strong>Results: </strong>1246 patients were included in <i>GPP-only</i>, 1384 in <i>GPP + PsO</i>, 2630 in <i>All-GPP</i> and 127,540 in <i>plaque-PsO-only</i>. 19,641,441 individuals were included in <i>general population</i>. The maximum follow-up ranged from 36.14 to 41.28 months (3.01-3.44 years). At 365-day follow-up, mortality risk was significantly higher in the <i>All-GPP</i> vs the <i>general population</i> (hazard ratio [HR] 4.93, 95% confidence interval [CI] 2.24-10.88) and <i>plaque-PsO-only</i> (HR 2.31, 95% CI 1.32-4.04) cohorts. At maximum follow-up, the mortality risk for the <i>All-GPP</i> cohort was four times higher than the <i>general population</i> (HR 3.98, 95% CI 2.92-5.43) and 1.5 times higher than the <i>plaque-PsO-only</i> (HR 1.49, 95% CI 1.20-1.85) cohorts.</p><p><strong>Conclusion: </strong>Patients with GPP exhibited an elevated mortality risk in comparison to the matched <i>plaque-PsO</i> and <i>general population</i> cohorts.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"115-123"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network.","authors":"Samip Sheth, Karla Inestroza, Joseph F Merola, Brittany Weber, Michael Garshick","doi":"10.1177/24755303251337020","DOIUrl":"10.1177/24755303251337020","url":null,"abstract":"<p><p>Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are at significantly increased risk for cardiovascular (CV) disease, attributed to chronic systemic inflammation and a high burden of cardiometabolic comorbidities. Despite this, CV risk factors in this population are frequently underdiagnosed and undertreated. This consensus document, developed by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN), provides practical recommendations for dermatologists, rheumatologists, and primary care physicians to improve CV risk assessment and management in PsO and PsA. Key recommendations include conducting baseline CV risk assessments at diagnosis-particularly for patients with moderate-to-severe PsO, PsA, or those requiring biologic therapy-and routine screening for hypertension, diabetes, dyslipidemia, smoking, obesity, and metabolic syndrome. The use of biomarkers such as high-sensitivity C-reactive protein and lipoprotein(a) may help refine risk stratification. Patients at elevated risk should be referred to their primary care provider or a cardiologist for further evaluation and may require additional imaging, including coronary artery calcium scoring. Lifestyle counseling on diet, exercise, weight management, and smoking cessation is essential. Pharmacologic strategies, such as earlier initiation of statins and consideration of glucagon-like peptide-1 (GLP-1) receptor agonists, are encouraged when clinically appropriate. Systemic inflammation should be reduced using anti-inflammatory therapies, although outcome data remain mixed. Clinicians must carefully assess the risks and benefits of NSAIDs, corticosteroids, and Janus kinase (JAK) inhibitors. This document aims to bridge existing gaps in interdisciplinary care and facilitate earlier, more aggressive CV risk management in psoriatic disease, aligning with current cardiology and dermatology guidelines to reduce morbidity and mortality.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"124-130"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling Psoriasis Flare-up and Dengue Infection.","authors":"Bárbara Agustina Hernández, Paula Carolina Luna, Cristina Echeverria, Mariana Barbetti, Maria Julia Cura, Enrique Soriano, Luis Daniel Mazzuoccolo","doi":"10.1177/24755303251344190","DOIUrl":"10.1177/24755303251344190","url":null,"abstract":"<p><strong>Importance: </strong>Dengue infection is an emerging global health concern. Understanding its impact on patients with a history of psoriasis is essential, particularly concerning its potential to trigger psoriasis flare-ups. Additionally, it is crucial to assess the influence of psoriasis treatments on the severity of dengue.</p><p><strong>Objectives: </strong>This study aims to describe the effects of dengue infection on psoriasis exacerbations, in patients with pre-existing psoriasis and to assess whether prior psoriasis treatment influences dengue severity.</p><p><strong>Design: </strong>A cross-sectional descriptive study.</p><p><strong>Main outcomes and measures: </strong>Demographic, clinical, and treatment data were systematically collected.</p><p><strong>Results: </strong>25 dermatologists reported psoriasis flare-ups in 52 patients (67.3% male; median age 48 years, IQR 23-81). Among these patients, 63.5% (33 patients) experienced plaque psoriasis flare-ups, 19.2% (10 patients) developed guttate psoriasis, 11.5% (6 patients) progressed to erythroderma, 3.8% (2 patients) presented with plaque psoriasis and pustules, and one patient (1.9%) had an acute generalized pustular psoriasis flare-up. Overall, 63.5% of patients experienced moderate dengue, 30.8% had mild dengue, and 5.8% had severe dengue. Among the 19 patients receiving biologic treatments, 84.2% experienced moderate dengue, while 15.8% had mild dengue. Importantly, none of these patients required hospitalization for severe dengue. In the methotrexate-treated group, comprising seven patients, four experienced mild dengue and three had moderate dengue. Psoriasis flare-ups in this group included two severe cases, five moderate cases, one erythroderma, and six cases of plaque psoriasis.</p><p><strong>Conclusions and relevance: </strong>Dengue infection appears to trigger psoriasis flare-ups in affected individuals. The most commonly observed type was plaque psoriasis. Our findings suggest systemic therapies for psoriasis may not exacerbate dengue severity and could be considered safe. Further prospective studies are necessary to elucidate the relationship between psoriasis severity and dengue outcomes.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251344190"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}